A roadmap for affordable genetic medicines.

Area of Science:

• Biotechnology
• Genetics
• Medical Economics

Background:

• The US Food and Drug Administration has approved twenty genetic therapies, including the first CRISPR-based gene-editing therapy for sickle cell disease, CASGEVY.
• These advanced therapies offer significant promise for treating genetic disorders and cancers but are associated with extremely high costs, exceeding $4 million per patient.

Purpose of the Study:

• To address the high cost and limited accessibility of newly approved genetic therapies.
• To propose sustainable, alternative models for the development and commercialization of genetic therapies from discovery to market.

Main Methods:

• Convening a multidisciplinary task force to develop recommendations.
• Proposing a new pricing structure and a business model for genetic therapy development.
• Outlining strategies involving academic licensing, manufacturing innovation, and regulatory support.

Main Results:

• A proposed pricing structure could potentially reduce per-patient costs by tenfold.
• A new business model distributing responsibilities and leveraging diverse funding sources is outlined.
• Strategies for cost reduction through academic licensing, manufacturing, and regulation are presented.

Conclusions:

• Sustainable alternatives are crucial to enhance affordability and access to transformative genetic therapies.
• Implementing proposed pricing and business models, alongside supportive regulations and manufacturing innovations, can broaden patient access to treatments like CASGEVY.